Current Report Filing (8-k)
June 13 2017 - 4:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2017
Commission File Number:
0-24260
Amedisys, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
11-3131700
|
|
(State or other jurisdiction of
|
|
(IRS Employer
|
|
incorporation or organization)
|
|
Identification No.)
|
3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225)
292-2031
or (800)
467-2662
(Registrant’s telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2 below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
Amedisys, Inc. (the
“Company”) held its annual meeting of stockholders on Thursday, June 8, 2017 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four proposals. A brief description of and tabulation of
votes for each proposal are set forth below.
Proposal 1
. The Company’s stockholders elected the following nine directors for
a term of one year. There were 1,924,511 broker
non-votes
with respect to the proposal.
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
|
Withheld
|
|
|
Linda J. Hall, PhD
|
|
|
29,873,285
|
|
|
|
163,099
|
|
|
Julie D. Klapstein
Paul B. Kusserow
|
|
|
29,872,547
29,907,671
|
|
|
|
163,837
128,713
|
|
|
Richard A. Lechleiter
|
|
|
29,828,584
|
|
|
|
207,800
|
|
|
Jake L. Netterville
|
|
|
29,752,602
|
|
|
|
283,782
|
|
|
Bruce D. Perkins
|
|
|
29,872,727
|
|
|
|
163,657
|
|
|
Jeffrey A. Rideout, MD
|
|
|
29,873,267
|
|
|
|
163,117
|
|
|
Donald A. Washburn
|
|
|
29,377,529
|
|
|
|
658,855
|
|
|
Nathaniel M. Zilkha
|
|
|
23,661,294
|
|
|
|
6,375,090
|
|
Proposal 2
. The Company’s stockholders ratified the selection of KPMG LLP as the Company’s
independent registered public accountants for the fiscal year ending December 31, 2017. There were no broker
non-votes
with respect to the proposal.
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
31,473,521
|
|
455,120
|
|
32,254
|
Proposal 3
. The Company’s stockholders approved, on an advisory
(non-binding)
basis, the compensation paid to the Company’s named executive officers. There were 1,924,511 broker
non-votes
with respect to the proposal.
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
28,875,091
|
|
1,095,554
|
|
65,739
|
Proposal 4
. The Company’s stockholders expressed their preference to conduct future advisory votes
on executive compensation every year. Consistent with the recommendation of the Board of Directors of the Company as set forth in the Company’s proxy statement for the Annual Meeting and the vote of the stockholders at the Annual Meeting, the
Board of Directors has determined to include an advisory stockholder vote on executive compensation in the Company’s proxy materials every year. This policy will remain in effect until the next stockholder vote on the frequency of stockholder
votes on executive compensation.
|
|
|
|
|
|
|
|
|
One Year
|
|
Two Years
|
|
Three Years
|
|
Abstain
|
|
24,780,486
|
|
4,912
|
|
5,235,603
|
|
15,383
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
AMEDISYS, INC.
|
|
|
|
|
By:
|
|
/s/ Paul B. Kusserow
|
|
Paul B. Kusserow
|
|
President and Chief Executive Officer
|
|
|
|
DATE: June 13, 2017
|
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024
